Literature DB >> 17459931

Enhanced antiviral activity against foot-and-mouth disease virus by a combination of type I and II porcine interferons.

Mauro Pires Moraes1, Teresa de Los Santos, Marla Koster, Traci Turecek, He Wang, Vladimir G Andreyev, Marvin J Grubman.   

Abstract

Previously, we showed that type I interferon (alpha/beta interferon [IFN-alpha/beta]) can inhibit foot-and-mouth disease virus (FMDV) replication in cell culture, and swine inoculated with 10(9) PFU of human adenovirus type 5 expressing porcine IFN-alpha (Ad5-pIFN-alpha) were protected when challenged 1 day later. In this study, we found that type II pIFN (pIFN-gamma) also has antiviral activity against FMDV in cell culture and that, in combination with pIFN-alpha, it has a synergistic antiviral effect. We also observed that while each IFN alone induced a number of IFN-stimulated genes (ISGs), the combination resulted in a synergistic induction of some ISGs. To extend these studies to susceptible animals, we inoculated groups of swine with a control Ad5, 10(8) PFU of Ad5-pIFN-alpha, low- or high-dose Ad5-pIFN-gamma, or a combination of Ad5-pIFN-alpha and low- or high-dose Ad5-pIFN-gamma and challenged all groups with FMDV 1 day later. The control group and the groups inoculated with either Ad5-pIFN-alpha or a low dose of Ad5-pIFN-gamma developed clinical disease and viremia. However, the group that received the combination of both Ad5-IFNs with the low dose of Ad5-pIFN-gamma was completely protected from challenge and had no viremia. Similarly the groups inoculated with the combination of Ad5s with the higher dose of Ad5-pIFN-gamma or with only high-dose Ad5-pIFN-gamma were protected. The protected animals did not develop antibodies against viral nonstructural (NS) proteins, while all infected animals were NS protein seropositive. No antiviral activity or significant levels of IFNs were detected in the protected groups, but there was an induction of some ISGs. The results indicate that the combination of type I and II IFNs act synergistically to inhibit FMDV replication in vitro and in vivo.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17459931      PMCID: PMC1933294          DOI: 10.1128/JVI.02775-06

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  74 in total

Review 1.  Foot-and-mouth disease.

Authors:  Marvin J Grubman; Barry Baxt
Journal:  Clin Microbiol Rev       Date:  2004-04       Impact factor: 26.132

2.  Interplay between alpha/beta and gamma interferons with B, T, and natural killer cells in the defense against herpes simplex virus type 1.

Authors:  Sabine Vollstedt; Susi Arnold; Cornelia Schwerdel; Marco Franchini; Gottfried Alber; James P Di Santo; Mathias Ackermann; Mark Suter
Journal:  J Virol       Date:  2004-04       Impact factor: 5.103

Review 3.  Transcriptional activation of alpha/beta interferon genes: interference by nonsegmented negative-strand RNA viruses.

Authors:  Karl-Klaus Conzelmann
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

4.  The infectivity assay of foot-and-mouth disease virus in pigs.

Authors:  R Burrows
Journal:  J Hyg (Lond)       Date:  1966-12

5.  Indoleamine 2,3-dioxygenase mediates cell type-specific anti-measles virus activity of gamma interferon.

Authors:  Karola Obojes; Oliver Andres; Kwang Sik Kim; Walter Däubener; Jürgen Schneider-Schaulies
Journal:  J Virol       Date:  2005-06       Impact factor: 5.103

6.  Role of indoleamine-2,3-dioxygenase in alpha/beta and gamma interferon-mediated antiviral effects against herpes simplex virus infections.

Authors:  O Adams; K Besken; C Oberdörfer; C R MacKenzie; O Takikawa; W Däubener
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

7.  Immediate protection of swine from foot-and-mouth disease: a combination of adenoviruses expressing interferon alpha and a foot-and-mouth disease virus subunit vaccine.

Authors:  Mauro P Moraes; Jarasvech Chinsangaram; Mario C S Brum; Marvin J Grubman
Journal:  Vaccine       Date:  2003-12-12       Impact factor: 3.641

8.  CXC chemokine ligand 10 controls viral infection in the central nervous system: evidence for a role in innate immune response through recruitment and activation of natural killer cells.

Authors:  Matthew J Trifilo; Cynthia Montalto-Morrison; Linda N Stiles; Kelley R Hurst; Jenny L Hardison; Jerry E Manning; Paul S Masters; Thomas E Lane
Journal:  J Virol       Date:  2004-01       Impact factor: 5.103

9.  Prevention of lethal respiratory vaccinia infections in mice with interferon-alpha and interferon-gamma.

Authors:  Ge Liu; Qingzhu Zhai; Dustin J Schaffner; Aiguo Wu; Adiamseged Yohannes; Tanisha M Robinson; Matt Maland; Jay Wells; Thomas G Voss; Charlie Bailey; Ken Alibek
Journal:  FEMS Immunol Med Microbiol       Date:  2004-04-09

10.  Interferon-beta and interferon-gamma synergistically inhibit the replication of severe acute respiratory syndrome-associated coronavirus (SARS-CoV).

Authors:  Bruno Sainz; Eric C Mossel; C J Peters; Robert F Garry
Journal:  Virology       Date:  2004-11-10       Impact factor: 3.616

View more
  33 in total

1.  Anti-foot-and-mouth disease virus effects of Chinese herbal kombucha in vivo.

Authors:  Naifang Fu; Juncai Wu; Lv Lv; Jijun He; Shengjun Jiang
Journal:  Braz J Microbiol       Date:  2015-10-09       Impact factor: 2.476

2.  Accessory-cell-mediated activation of porcine NK cells by toll-like receptor 7 (TLR7) and TLR8 agonists.

Authors:  Felix N Toka; Charles K Nfon; Harry Dawson; William T Golde
Journal:  Clin Vaccine Immunol       Date:  2009-04-15

3.  Robust Protection against Highly Virulent Foot-and-Mouth Disease Virus in Swine by Combination Treatment with Recombinant Adenoviruses Expressing Porcine Alpha and Gamma Interferons and Multiple Small Interfering RNAs.

Authors:  Su-Mi Kim; Jong-Hyeon Park; Kwang-Nyeong Lee; Se-Kyung Kim; Su-Hwa You; Taeseong Kim; Dongseob Tark; Hyang-Sim Lee; Min-Goo Seo; Byounghan Kim
Journal:  J Virol       Date:  2015-06-03       Impact factor: 5.103

4.  Inoculation of swine with foot-and-mouth disease SAP-mutant virus induces early protection against disease.

Authors:  Fayna Díaz-San Segundo; Marcelo Weiss; Eva Pérez-Martín; Camila C Dias; Marvin J Grubman; Teresa de los Santos
Journal:  J Virol       Date:  2011-11-23       Impact factor: 5.103

5.  Foot-and-mouth disease virus 3C protease cleaves NEMO to impair innate immune signaling.

Authors:  Dang Wang; Liurong Fang; Kui Li; Huijuan Zhong; Jinxiu Fan; Chao Ouyang; Huan Zhang; Erzhen Duan; Rui Luo; Zhongming Zhang; Xiangtao Liu; Huanchun Chen; Shaobo Xiao
Journal:  J Virol       Date:  2012-06-20       Impact factor: 5.103

6.  Interferon-induced protection against foot-and-mouth disease virus infection correlates with enhanced tissue-specific innate immune cell infiltration and interferon-stimulated gene expression.

Authors:  Fayna Diaz-San Segundo; Mauro P Moraes; Teresa de Los Santos; Camila C A Dias; Marvin J Grubman
Journal:  J Virol       Date:  2009-12-02       Impact factor: 5.103

Review 7.  New insights on adenovirus as vaccine vectors.

Authors:  Marcio O Lasaro; Hildegund C J Ertl
Journal:  Mol Ther       Date:  2009-06-09       Impact factor: 11.454

8.  A conserved domain in the leader proteinase of foot-and-mouth disease virus is required for proper subcellular localization and function.

Authors:  Teresa de los Santos; Fayna Diaz-San Segundo; James Zhu; Marla Koster; Camila C A Dias; Marvin J Grubman
Journal:  J Virol       Date:  2008-12-03       Impact factor: 5.103

9.  Constitutively Active IRF7/IRF3 Fusion Protein Completely Protects Swine against Foot-and-Mouth Disease.

Authors:  Lisbeth Ramírez-Carvajal; Fayna Diaz-San Segundo; Elizabeth Ramirez-Medina; Luis L Rodríguez; Teresa de Los Santos
Journal:  J Virol       Date:  2016-09-12       Impact factor: 5.103

10.  Expression of porcine fusion protein IRF7/3(5D) efficiently controls foot-and-mouth disease virus replication.

Authors:  Lisbeth Ramírez-Carvajal; Fayna Díaz-San Segundo; Danielle Hickman; Charles R Long; James Zhu; Luis L Rodríguez; Teresa de los Santos
Journal:  J Virol       Date:  2014-07-16       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.